On May 29, 2018 BerGenBio ASA (OSE: BGBIO) reported it will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib (Press release, BerGenBio, MAY 29, 2018, View Source [SID1234527034]). The data will be presented at the Annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting and at a reception hosted by BerGenBio (details below).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call details:
The call will be hosted by BerGenBio senior management and take place on:
Monday, 4 June 2018 at 8:30 AM CEST.
To take part, please dial in 5-10 minutes prior to the scheduled start using below phone number and confirmation code 1068189:

Norway +47 2100 2608
United Kingdom +44 (0)330 336 9106
United States +1 323-794-2594

A slide deck presentation to accompany the call will be made available at www.bergenbio.com in the Investors / Presentations section from 8:00 AM CEST on 4 June 2018.

Presentations to be made during the annual ASCO (Free ASCO Whitepaper) meeting:
Saturday 2 June, 6:00 – 8:00 PM CDT, Chicago School of the Art Institute, Chicago, IL
BerGenBio private reception

New interim Phase II clinical trial data with bemcentinib and selected pre-clinical data to be discussed by BerGenBio principal investigators and invited key opinion leaders
For further details and to receive an invitation, please click here
Monday 4 June, 8:00 AM – 11:30 AM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBC008 – Poster Board: #292, Abstract 3078
Interim clinical data from clinical trial ref. BGBC003 – Poster Board: #80, Abstract 7020
To be discussed at the Poster Discussion Session. 11:30 AM – 12:45 PM
Biomarker study – Poster Board: #385, Abstract 2559
Monday 4 June, 1:15 PM – 4:45 PM CDT, ASCO (Free ASCO Whitepaper) Annual Meeting, McCormick Center, Chicago, IL

Interim clinical data from clinical trial ref. BGBIL006 – Poster Board: #375, Abstract 9548
The posters presented at ASCO (Free ASCO Whitepaper) will be made available www.bergenbio.com in the Investors / Presentations section at the time of presentation.

On May 29, 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, reported it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 (Press release, AbbVie, MAY 29, 2018, View Source [SID1234527051]). Richard A. Gonzalez, chairman and chief executive officer, will present at 10 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

On May 29, 2018 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), reported that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4th at 9:00a PDT / 12:00p EDT at the Luxe Sunset Bel Air Hotel in Los Angeles (Press release, Onconova, MAY 29, 2018, View Source [SID1234527102]). Mr. Mark Guerin, Chief Financial Officer of Onconova, will be giving the presentation and meeting with investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The event is slated to be our largest Invitational to date," stated Chris Lahiji, President of LD Micro. "When the fires caused the cancellation of our Main Event back in December, we vowed to come back even stronger. This event showcases our firm’s ability to attract the most unique and exciting names in micro-cap."

The conference will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals.

On May 29, 2018 Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that management will present a company update at the Jefferies 2018 Global Healthcare Conference in New York, NY (Press release, Bicycle Therapeutics, MAY 29, 2018, View Source [SID1234526927]). The presentation will take place at 1:30 p.m. on Tuesday, June 5, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 29, 2018 Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center reported a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS) (Press release, Ipsen, MAY 29, 2018, View Source [SID1234527087]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.

Alexandre Lebeaut, M.D., Executive Vice President, Research & Development and Chief Scientific Officer, Ipsen, commented, "We are very pleased to partner with the IACS at the MD Anderson Cancer Center whose reputation in scientific excellence and clinical care in Oncology is outstanding. Through this collaboration, we aim to synergize IACS’ scientific expertise with Ipsen’s drug development capabilities to deliver innovative therapies more rapidly to patients in need, and advance patient care in Oncology"

MD Anderson and Ipsen also will collaborate to conduct additional pre-clinical studies to further explore the potential of the drug candidate’s mode-of-action and expanded indications. The detailed financial terms of the agreement, including development and commercial milestones and royalties, have not been disclosed.

"We believe this partnership has the potential to deliver a new therapeutic option to our patients," said Stephen Hahn, M.D., chief medical executive at MD Anderson. "This focus on accelerating the development of efficient treatments is vital to our mission of ending cancer and to providing the very best care we can to those who need it most."